ArticleESMO open2021
European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN.
Open access · goldAbstract readConsensus Statement
In one paragraph
Article in ESMO open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Patient-centred and fit-for-purpose clinical trials in rare cancers: lessons from sarcomas for operationalising 2024 WHO Guidance and ICH E6(R3).EClinicalMedicine · 2026Review
- Networking is Essential for the Proper Management of Rare Cancers: From Recognition to Implementation.Annals of surgical oncology · 2026Article
- Developing a rare disease registry for inherited metabolic disorders in Pakistan.Orphanet journal of rare diseases · 2026Article
- Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.EClinicalMedicine · 2026Article
- Molecularly redefining small bowel adenocarcinoma to accelerate precision patient care - protocol of a multicenter observational cohort biomarker study.BMC cancer · 2025Article
- Beyond the sarcoma center: establishing the Sarcoma HASM network-a Hub and Spoke Model network for global integrated and precision care.ESMO open · 2024Article
- From Data Integration to Precision Medicine: A Value-Based Healthcare Approach for Sarcoma Care.Journal of clinical medicine · 2024Review
- The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors.Cancers · 2024Review
- Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.Cancers · 2024Article
- Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN.The Lancet regional health. Europe · 2024Review
- Challenges and opportunities for sarcoma care and research in Latin America: a position paper from the LACOG sarcoma group.Lancet regional health. Americas · 2024Review
- Addressing disparities in European cancer outcomes: a qualitative study Protocol of the BEACON project.Frontiers in psychology · 2024Article
- The arisal of data spaces: why I am excited and worried.Frontiers in immunology · 2024Article
- From National to International Collaboration in Gestational Trophoblastic Disease: Hurdles and Possibilities.Gynecologic and obstetric investigation · 2024Review
- NUT carcinoma of the submandibular gland: A case report.Cancer reports (Hoboken, N.J.) · 2023Article
- The Next Frontier in Sarcoma Care: Digital Health, AI, and the Quest for Precision Medicine.Journal of personalized medicine · 2023Article
- European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Article
- Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.International journal of cancer · 2023Article
- The European Reference Network: the keystone for the management of rare thoracic cancers.Mediastinum (Hong Kong, China) · 2023Article
- Quality of Sarcoma Care: Longitudinal Real-Time Assessment and Evidence Analytics of Quality Indicators.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 20 institutions in 13 countries.
J-Y BlayDepartment of Medical Oncology, Centre Leon Berard & Centre de Recherche en Cancérologie de Lyon (CRCL) & Université Claude Bernard Lyon 1, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.
P CasaliDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.
C BouvierNeuroendocrine Cancer Unit, Royal Free Hospital, London, UK.
C DehaisSorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
I GallowayMelanoma Patient Network Europe, OcuMel, Birmingham, UK.
J GietemaDepartment of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
J HalámkováDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
N HindiInstitute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Virgen, Virgen del Rocío University Hospital, Seville, Spain.
A IdbaihSorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
E KinlochSalivary Gland Cancer, London, UK.
H-J KlümpenDepartment of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
T KolarovaInternational Neuroendocrine Cancer Alliance, Boston, USA.
K KopeckovaDepartment of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
J LoveyNational Institute of Oncology, Budapest, Hungary.
M MagalhaesOncology Department, Centro Hospitalar e Universitário Universitário do Porto, Porto, Portugal.
K OselinDepartment of Chemotherapy, Clinic of Haematology and Oncology, North Estonia Medical Centre Foundation, Tallinn, Estonia.
S Piperno-NeumannMedical Oncology Department, Institut Curie, Paris, France.
A RavnsbaekOncology Department, and Danish Centre for Particle Therapy, University Hospital, Aarhus, Denmark.
M RogasikResearch and Innovation Department, Centre Léon Bérard, Lyon, France.
A SafwatOncology Department, and Danish Centre for Particle Therapy, University Hospital, Aarhus, Denmark.
S ScheiplMedical University of Graz, Graz, Austria.
M SecklDepartment of Medical Oncology, Charing Cross Hospital Campus of Imperial College London, London, UK.
J TaylorThyroid Cancer Alliance, Rotterdam, The Netherlands.
M TemnykMaria Skłodowska Curie Institute, Warsaw, Poland.
A TramaDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.
M UrbonasLithuanian University of Health Sciences, Department of Neurosurgery, Kaunas, Lithuania.
M WartenbergSarcoma Patient EuroNet.
A WeinmanEURORDIS-Rare Diseases Europe (European Patient Organisation for Rare Diseases).
EURACAN Network
Danish Pain Research Center · DKFondazione IRCCS Istituto Nazionale dei Tumori · ITAmsterdam University Medical Centers · NLCentre de Recherche en Cancérologie de Lyon · FRCentre Léon Bérard · FRCentro Hospitalar do Porto · PTCharing Cross Hospital · GBCharles University · CZEuropean Organisation for Rare Diseases · FRInstitut Curie · FRInstituto de Biomedicina de Sevilla · ESLithuanian University of Health Sciences · LTMasaryk Memorial Cancer Institute · CZMedical University of Graz · ATNational Institute of Oncology · HUNorth Estonia Medical Centre · EEPitié-Salpêtrière Hospital · FRSorbonne Université · FRThe Maria Sklodowska-Curie National Research Institute of Oncology · PLThe Royal Free Hospital · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
NeoplasmsDelivery of Health CareHumansRare Diseases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.